Back to GetFilings.com
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
-----------------------------
FORM 10-Q
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
October 31, 2003 0-11088
For the quarterly period ended Commission file number
ALFACELL CORPORATION
(Exact name of registrant as specified in its charter)
Delaware 22-2369085
(State or other jurisdiction of (I.R.S. Employer Identification No.)
organization)
225 Belleville Avenue, Bloomfield, New Jersey 07003
(Address of principal executive offices) (Zip Code)
(Registrant's telephone number, including area code) (973) 748-8082
NOT APPLICABLE
(Former name, former address, and former fiscal year, if
changed since last report.)
Indicate by check mark whether the registrant has (1) filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes |X| No |_|
Indicate by check mark whether the registrant is an accelerated filer (as
defined in Exchange Act Rule 12b-2). Yes |_| No |X|
The number of shares of common stock, $.001 par value, outstanding as of
December 10, 2003 was 28,421,983 shares.
ALFACELL CORPORATION
(A Development Stage Company)
PART I. FINANCIAL INFORMATION
Item 1. Financial Statements
BALANCE SHEETS
October 31, 2003 and July 31, 2003
October 31,
2003 July 31,
ASSETS (Unaudited) 2003
------------ ------------
Current assets:
Cash and cash equivalents $ 1,369,254 $ 330,137
Income tax receivable 221,847 --
Other current assets 107,397 10,103
------------ ------------
Total current assets 1,698,498 340,240
Property and equipment, net 13,496 12,795
Loan receivable, related party 145,433 142,287
------------ ------------
Total assets $ 1,857,427 $ 495,322
============ ============
LIABILITIES AND STOCKHOLDERS' DEFICIENCY
Current liabilities:
Current portion of long-term debt, net of debt discount of $189,304 at October 31,
2003 and $187,121 at July 31, 2003 $ 735,159 $ 637,080
Accounts payable 642,190 699,429
Accrued expenses 918,234 1,407,978
------------ ------------
Total current liabilities 2,295,583 2,744,487
Long-term debt, less current portion, net of debt discount of $72,695 at October 31,
2003 and $163,687 at July 31, 2003 231,303 242,516
------------ ------------
Total liabilities 2,526,886 2,987,003
------------ ------------
Stockholders' deficiency:
Preferred stock, $.001 par value;
Authorized and unissued, 1,000,000 shares at October 31, 2003 and July 31, 2003 -- --
Common stock $.001 par value;
Authorized 40,000,000 shares at October 31, 2003 and July 31, 2003;
Issued and outstanding, 28,248,658 shares at October 31, 2003 and 25,026,129
shares at July 31, 2003 28,249 25,026
Capital in excess of par value 64,034,710 61,457,502
Deficit accumulated during development stage (64,732,418) (63,974,209)
------------ ------------
Total stockholders' deficiency (669,459) (2,491,681)
------------ ------------
Total liabilities and stockholders' deficiency $ 1,857,427 $ 495,322
============ ============
See accompanying notes to financial statements.
- 2 -
ALFACELL CORPORATION
(A Development Stage Company)
STATEMENTS OF OPERATIONS
Three months ended October 31, 2003 and 2002,
and the Period from August 24, 1981
(Date of Inception) to October 31, 2003
(Unaudited)
Three Months Ended August 24, 1981
October 31, (Date of Inception)
----------- to
2003 2002 October 31, 2003
---- ---- ----------------
Revenue:
Sales $ -- $ -- $ 553,489
Investment income 3,700 114 1,390,700
Other income -- 30,000 90,103
------------ ------------ ------------
Total revenue 3,700 30,114 2,034,292
------------ ------------ ------------
Costs and expenses:
Cost of sales -- -- 336,495
Research and development 637,197 419,504 42,239,132
General and administrative 227,945 135,756 22,515,797
Interest:
Related parties -- -- 1,147,547
Others 118,614 34,228 2,541,924
------------ ------------ ------------
Total costs and expenses 983,756 589,488 68,780,895
------------ ------------ ------------
Loss before state tax benefit (980,056) (559,374) (66,746,603)
State tax benefit 221,847 229,459 2,014,185
------------ ------------ ------------
Net loss $ (758,209) $ (329,915) $(64,732,418)
============ ============ ============
Loss per basic and diluted common share $ (0.03) $ (0.01)
============ ============
Weighted average number of shares outstanding 26,911,796 22,787,272
============ ============
See accompanying notes to financial statements.
- 3 -
ALFACELL CORPORATION
(A Development Stage Company)
STATEMENTS OF CASH FLOWS
Three months ended October 31, 2003 and 2002,
and the Period from August 24, 1981
(Date of Inception) to October 31, 2003
(Unaudited)
Three Months Ended August 24, 1981
October 31, (Date of Inception)
----------- to
2003 2002 October 31, 2003
---- ---- ----------------
Cash flows from operating activities:
Net loss $ (758,209) $(329,915) $(64,732,418)
Adjustments to reconcile net loss to
net cash used in operating activities:
Gain on sale of marketable securities -- -- (25,963)
Depreciation and amortization 1,550 5,709 1,548,768
Loss on disposal of property and equipment -- -- 18,926
Noncash operating expenses 5,235 29,049 6,122,847
Amortization of debt discount 88,542 -- 331,953
Amortization of deferred compensation -- -- 11,442,000
Amortization of organization costs -- -- 4,590
Changes in assets and liabilities:
Increase in income tax receivable (221,847) (229,459) (221,847)
(Increase) decrease in other current assets (97,294) 8,601 (167,264)
Increase in loan receivable-related party (3,146) -- (49,382)
Increase in interest payable-related party -- -- 744,539
(Decrease) increase in accounts payable (57,239) (15,737) 1,096,649
Increase in accrued payroll and
expenses, related parties -- -- 2,348,145
(Decrease) increase in accrued expenses (489,744) 203,100 1,459,747
----------- --------- ------------
Net cash used in operating activities (1,532,152) (328,652) (40,078,710)
----------- --------- ------------
Cash flows from investing activities:
Purchase of marketable equity securities -- -- (290,420)
Proceeds from sale of marketable equity securities -- -- 316,383
Purchase of property and equipment (2,251) -- (1,409,087)
Patent costs -- -- (97,841)
----------- --------- ------------
Net cash used in investing activities (2,251) -- (1,480,965)
----------- --------- ------------
(continued)
See accompanying notes to financial statements.
- 4 -
ALFACELL CORPORATION
(A Development Stage Company)
STATEMENTS OF CASH FLOWS, Continued
Three months ended October 31, 2003 and 2002
and the Period from August 24, 1981
(Date of Inception) to October 31, 2003
(Unaudited)
Three Months Ended August 24, 1981
October 31, (Date of Inception)
----------- to
2003 2002 October 31, 2003
---- ---- ----------------
Cash flows from financing activities:
Proceeds from short-term borrowings $ -- $ 25,000 $ 874,500
Payment of short-term borrowings -- (5,000) (653,500)
Increase in loans payable - related party, net -- -- 2,628,868
Proceeds from bank debt and other long-term debt, net of
costs -- 250,000 3,667,460
Reduction of bank debt and long-term debt (1,676) (1,954) (2,952,840)
Proceeds from issuance of common stock, net 1,527,925 7,000 31,542,263
Proceeds from exercise of stock options and warrants, net 1,047,271 9,958 7,108,185
Proceeds from issuance of convertible debentures, related party -- -- 297,000
Proceeds from issuance of convertible debentures, unrelated party -- -- 416,993
---------- ---------- ------------
Net cash provided by financing activities 2,573,520 285,004 42,928,929
---------- ---------- ------------
Net increase (decrease) in cash and cash equivalents 1,039,117 (43,648) 1,369,254
Cash and cash equivalents at beginning of period 330,137 85,843 --
---------- ---------- ------------
Cash and cash equivalents at end of period $1,369,254 $ 42,195 $ 1,369,254
========== ========== ============
Supplemental disclosure of cash flow information - interest
paid $ 30,072 $ 11,065 $ 1,737,410
========== ========== ============
Noncash financing activities:
Issuance of convertible subordinated debenture for loan payable
to officer $ -- $ -- $ 2,725,000
========== ========== ============
Issuance of common stock upon the conversion of convertible
subordinated debentures, related party $ -- $ -- $ 3,242,000
========== ========== ============
Conversion of short-term borrowings to common stock $ -- $ -- $ 226,000
========== ========== ============
Conversion of accrued interest, payroll and expenses by related
parties to stock options $ -- $ -- $ 3,194,969
========== ========== ============
Repurchase of stock options from related party $ -- $ -- $ (198,417)
========== ========== ============
Conversion of accrued interest to stock options $ -- $ -- $ 142,441
========== ========== ============
Conversion of accounts payable to common stock $ -- $ 10,000 $ 454,549
========== ========== ============
Conversion of notes payable, bank and accrued interest
to long-term debt $ -- $ -- $ 1,699,072
========== ========== ============
Conversion of loans and interest payable, related party and
accrued payroll and expenses, related parties to long-term
accrued payroll and other, related party $ -- $ -- $ 1,863,514
========== ========== ============
Issuance of common stock upon the conversion of convertible
subordinated debentures, other $ -- $ -- $ 191,993
========== ========== ============
Issuance of common stock for services rendered $ 60,000 $ -- $ 62,460
========== ========== ============
Issuance of warrants with notes payable $ -- $ -- $ 594,219
========== ========== ============
See accompanying notes to financial statements.
- 5 -
ALFACELL CORPORATION
(A Development Stage Company)
NOTES TO FINANCIAL STATEMENTS
(Unaudited)
1. ORGANIZATION AND BASIS OF PRESENTATION
In the opinion of management, the accompanying unaudited financial
statements contain all adjustments (consisting of normal recurring accruals)
necessary to present fairly the Company's financial position as of October 31,
2003 and its results of operations for the three month periods ended October 31,
2003 and 2002 and the period from August 24, 1981 (date of inception) to October
31, 2003. The results of operations for the three months ended October 31, 2003
are not necessarily indicative of the results to be expected for the full year.
Certain footnote disclosures normally included in financial statements
prepared in accordance with generally accepted accounting principles have been
omitted in accordance with the published rules and regulations of the Securities
and Exchange Commission. The financial statements in this report should be read
in conjunction with the financial statements and notes thereto included in the
Form 10-K for the year ended July 31, 2003.
The Company is a development stage company as defined in the Financial
Accounting Standards Board's Statement of Financial Accounting Standards No. 7.
The Company is devoting substantially all of its present efforts to establishing
a new business and developing new drug products. Its planned principal
operations have not commenced and, accordingly, no significant revenue has been
derived therefrom.
The Company has reported net losses since its inception. Also, the Company
has limited liquid resources. The report of the Company's independent public
accountants on the Company's July 31, 2003 financial statements included an
explanatory paragraph which states that the Company's recurring losses, working
capital deficit and limited liquid resources raise substantial doubt about the
Company's ability to continue as a going concern. Through October 31, 2003, the
Company continued to incur losses, had a working capital deficit and limited
liquid resources which raise substantial doubt about the Company's ability to
continue as a going concern. The financial statements at October 31, 2003 and
July 31, 2003 do not include any adjustments that might result from the outcome
of this uncertainty.
The Company's continued operations will depend on its ability to raise
additional funds through various potential sources such as equity and debt
financing, collaborative agreements, strategic alliances, sale of tax benefits,
revenues from the commercial sale of ONCONASE(R), licensing of its proprietary
RNase technology and its ability to realize the full potential of its technology
and its drug candidates via out-licensing agreements with other companies. Such
additional funds may not become available as needed or be available on
acceptable terms. Through October 31, 2003, a significant portion of the
Company's financing has been through private placements of common stock and
warrants, the issuance of common stock for stock options and warrants exercised
and for services rendered, debt financing and financing provided by the
Company's Chief Executive Officer. Additionally, the Company has raised capital
through the sale of its tax benefits. Until and unless the Company's operations
generate significant revenues, the Company will continue to fund its operations
from cash on hand and through the sources of capital previously described. From
August 1, 2003 through December 3, 2003, the Company received net proceeds of
approximately $2,660,000 from the private placement of common stock and warrants
and exercise of warrants and stock options. No assurances can be provided that
the additional capital will be sufficient to meet the Company's needs.
2. EARNINGS (LOSS) PER COMMON SHARE
"Basic" earnings (loss) per common share equals net income (loss) divided
by weighted average common shares outstanding during the period. "Diluted"
earnings per common share equals net income divided by the sum of weighted
average common shares outstanding during the period, adjusted for the
- 6 -
ALFACELL CORPORATION
(A Development Stage Company)
NOTES TO FINANCIAL STATEMENTS, Continued
(Unaudited)
2. EARNINGS (LOSS) PER COMMON SHARE, Continued
effects of potentially dilutive securities. The Company's Basic and Diluted per
share amounts are the same since the Company is in a loss position and the
assumed exercise of stock options and warrants would be all anti-dilutive. The
number of outstanding options and warrants that could dilute earnings per share
in future periods was 9,565,519 and 9,911,044 at October 31, 2003 and 2002,
respectively. This excludes the potential dilution that could occur upon the
conversion of (i) convertible notes into common stock and (ii) a second warrant
that will be issued to an institutional investor, permitting the investment of
an additional $1,500,000 to purchase the Company's common stock, assuming the
stockholders affirmatively vote to increase the number of authorized shares of
the Company at the annual meeting.
3. STOCK-BASED COMPENSATION
During the third fiscal quarter of 2003, Statement of Financial Accounting
Standards No. 148 (SFAS 148), "Accounting for Stock-Based Compensation -
Transition and Disclosure - An Amendment of FASB Statement No. 123" became
effective for the Company.
The Company measures compensation expense for its stock-based employee
compensation plans using the intrinsic value method. As the exercise price of
all options granted under these plans was equal to the fair market price of the
underlying common stock on the grant date, no stock-based employee compensation
cost is recognized in the condensed statements of operations.
In accordance with SFAS 148 and Statement of Financial Accounting
Standards No. 123, "Accounting for Stock-Based Compensation" (SFAS 123), the
Company's pro forma option expense is computed using the Black-Scholes option
pricing model. This model was developed for use in estimating the value of
traded options that have no vesting restrictions and are fully transferable. The
Company's employee stock options have characteristics significantly different
from those of traded options; therefore, in the opinion of management, the
Black-Scholes option pricing model required by SFAS 148 and SFAS 123, does not
necessarily provide a reliable measure of the fair value of the Company's
options.
To comply with SFAS 148, the Company is presenting the following table to
illustrate the effect on the net loss and loss per share if it had applied the
fair value recognition provisions of SFAS 123, as amended, to options granted
under the stock-based employee compensation plans. For purposes of this pro
forma disclosure, the estimated value of the options is amortized ratably to
expense over the options' vesting periods.
Three Months Ended
October 31,
-----------
2003 2002
---- ----
Net loss applicable to common shares
As reported $(758,209) $(329,915)
Stock-based employee compensation expense
under fair value method (71,179) (38,150)
--------- ---------
Pro forma $(829,388) $(368,065)
========= =========
Net loss per common share
As reported $ (0.03) $ (0.01)
Pro forma (0.03) (0.02)
- 7 -
ALFACELL CORPORATION
(A Development Stage Company)
NOTES TO FINANCIAL STATEMENTS, Continued
(Unaudited)
4. LOAN RECEIVABLE, RELATED PARTY
Amounts due from the Company's CEO totaling $145,433 as of October 31,
2003 are classified as a long-term asset as the loans have no specified due
dates, and the Company does not expect repayment of these amounts within one
year. These loans were made prior to July 30, 2002 and have not since been
materially modified. The Company earns interest at a rate of 8% per annum.
5. CAPITAL STOCK
In August 2003, the Company issued an aggregate of 120,000 shares of
common stock to private investors resulting in aggregate gross proceeds of
$60,000 to the Company. In addition, the private investors were granted
five-year warrants to purchase 120,000 shares of common stock at an exercise
price of $1.25 per share.
In August 2003, the Company issued 3,996 five-year stock options to a
consultant as payment for services rendered. The options vested immediately and
have a per share exercise price of $0.60. The Company recorded a total of $5,235
of non-cash expenses for these options, based upon the fair value on the date of
the issuance as estimated by the Black-Scholes options pricing model.
In September 2003, the Company issued 1,704,546 shares of common stock and
warrants to purchase 852,273 shares of common stock, at an exercise price of
$1.50 per share, to an institutional investor resulting in gross proceeds of
$1,500,000 to the Company. In addition, the Company agreed to grant the
institutional investor a second warrant to invest an additional $1,500,000 to
purchase the Company's common stock in the event the stockholder approval to
increase the authorized shares of common stock of the Company was obtained at
the annual meeting of stockholders to be held on January 14, 2004. The Company
also issued 38,710 shares of restricted common stock to a third party as
finder's fee.
In September 2003, the terms of the Company's convertible notes payable
were amended such that (i) they are convertible into 105,666 shares of Series A
Preferred Stock rather than common stock, and (ii) the warrants to be issued
upon the due date of the notes are warrants to purchase shares of Series A
Preferred Stock rather than common stock. In the event the stockholders approve
an increase in the number of shares of common stock authorized at the annual
meeting, the terms of the notes related to the conversion and exercise will
revert to the original terms to the extent the notes have not been converted. In
September 2003, the Company's Board of Directors designated 200,000 of the
1,000,000 authorized and unissued shares of preferred stock as Series A
Preferred Stock. 105,666 shares of the Company's Series A Preferred Stock have
been reserved for issuance upon the conversion of its convertible notes. As of
October 31, 2003, there were no shares of Preferred Stock outstanding. The
Series A Preferred Stock ranks pari passu to all of the Company's common stock,
both as to payment of dividends and as to distribution of assets upon the
liquidation, dissolution or winding up of the Company. The holder of each share
of Series A Preferred Stock is entitled to receive a dividend or distribution
equal to the product of (i) one hundred (100), multiplied by (ii) the dividend
or distribution to be received by each share of common stock. Each holder of
Series A Preferred Stock is entitled to one hundred (100) votes-per-share,
- 8 -
ALFACELL CORPORATION
(A Development Stage Company)
NOTES TO FINANCIAL STATEMENTS, Continued
(Unaudited)
5. CAPITAL STOCK, Continued
at any annual or special meeting of the stockholders at which the holders of
Common Stock are entitled to vote or pursuant to any written consent of the
holders of common stock. The holders of shares of Series A Preferred Stock shall
vote together as one class with the holders of common stock, on all matters
submitted to a vote of the stockholders of the Company.
During the quarter ended October 31, 2003, the Company issued an aggregate
of 1,359,273 shares of common stock upon the exercise of warrants by unrelated
parties and stock options by employees at per share exercise prices ranging from
$0.43 to $3.12. The Company realized aggregate gross proceeds of $1,047,271.
During the three months ended October 31, 2003, the Company incurred an
aggregate of $32,075 of costs relating to various private placements.
6. SALE OF NET OPERATING LOSSES
New Jersey has enacted legislation permitting certain corporations located
in New Jersey to sell state tax loss carryforwards and state research and
development credits or tax benefits. For the state fiscal year 2004 (July 1,
2003 to June 30, 2004), the Company has approximately $1,378,000 of total
available tax benefits, of which approximately $261,000 was allocated to be sold
between July 1, 2003 and June 30, 2004. Based on an agreement entered into by
the Company, the Company will receive approximately $222,000 from the sale of
its allocated tax benefits, which was recognized as a tax benefit for the
quarter ended October 31, 2003. In December 2002, the Company received
approximately $229,000 from the sale of its allocated tax benefits, which was
recognized as a tax benefit for the quarter ended October 31, 2002. The Company
will attempt to sell the remaining balance of its tax benefits in the amount of
approximately $1,117,000 between July 1, 2004 and June 30, 2005, subject to all
existing laws of the State of New Jersey. However, there is no assurance that
the Company will be able to find a buyer for its tax benefits or that such funds
will be available in a timely manner.
7. SUBSEQUENT EVENTS
From November 2003 through December 3, 2003, the Company issued to
unrelated parties and employees, an aggregate of 153,721 shares of common stock
upon the exercise of stock options at per share exercise prices ranging from
$0.26 to $0.94. The Company realized aggregate gross proceeds of $85,273.
- 9 -
Item 2. Management's Discussion and Analysis of Financial Condition and Results
of Operations.
Information herein contains, in addition to historical information,
forward-looking statements that involve risks and uncertainties. All statements,
other than statements of historical fact, regarding our financial position,
potential, business strategy, plans and objectives for future operations are
"forward-looking statements." These statements are commonly identified by the
use of forward-looking terms and phrases as "anticipates," "believes,"
"estimates," "expects," "intends," "may," "seeks," "should," or "will' or the
negative thereof or other variations thereon or comparable terminology, or by
discussions of strategy. We cannot assure you that the future results covered by
these forward-looking statements will be achieved. The matters set forth in
Exhibit 99.1 hereto constitute cautionary statements identifying important
factors with respect to these forward-looking statements, including certain
risks and uncertainties, that could cause actual results to vary significantly
from the future results indicated in these forward-looking statements. Other
factors could also cause actual results to differ significantly from the future
results indicated in these forward-looking statements.
Results of Operations
Three month periods ended October 31, 2003 and 2002
Revenues. We are a development stage company as defined in the Financial
Accounting Standards Board's Statement of Financial Accounting Standards No. 7.
We are devoting substantially all of our present efforts to establishing a new
business and developing new drug products. Our planned principal operations of
marketing and/or licensing of new drugs have not commenced and, accordingly, we
have not derived any significant revenue from these operations. We focus most of
our productive and financial resources on the development of ONCONASE(R) and as
such we have not had any sales in the three months ended October 31, 2003 and
2002. For the three months ended October 31, 2003, our investment income was
$3,700.
Research and Development. Research and development expense for the three
months ended October 31, 2003 was $637,000 compared to $420,000 for the same
period last year, an increase of $217,000, or 52%. This increase was primarily
due to the increase in data management fees related to our Phase III clinical
trial for malignant mesothelioma.
General and Administrative. General and administrative expense for the
three months ended October 31, 2003 was $228,000 compared to $136,000 for the
same period last year, an increase of $92,000, or 68%. This increase was
primarily due to increase in legal expenses related to business development
activities and increase in accounting fees.
Interest. Interest expense for the three months ended October 31, 2003 was
$119,000 compared to $34,000 for the same period last year, an increase of
$85,000. The increase was primarily due to the interest expense on the
amortization of debt discount on the notes payable and related warrants issued
to unrelated parties.
Income Taxes. New Jersey has enacted legislation permitting certain
corporations located in New Jersey to sell state tax loss carryforwards and
state research and development credits or tax benefits. For the state fiscal
year 2004 (July 1, 2003 to June 30, 2004), our Company has approximately
$1,378,000 of total available tax benefits of which approximately $261,000 was
allocated to be sold between July 1, 2003 and June 30, 2004. Based on an
agreement we entered into, we will receive approximately $222,000 from the sale
of the allocated tax benefits, which was recognized as a tax benefit for the
quarter ended October 31, 2003. In December 2002, we received approximately
$229,000 from the sale of the allocated tax benefits,
- 10 -
which was recognized as a tax benefit for the quarter ended October 31, 2002. We
will attempt to sell the remaining balance of our tax benefits in the amount of
approximately $1,117,000 between July 1, 2004 and June 30, 2005, subject to all
existing laws of the State of New Jersey. However, we cannot assure you that we
will be able to find a buyer for our tax benefits or that such funds will be
available in a timely manner.
Net Loss. We have incurred net losses during each year since our
inception. The net loss for the three months ended October 31, 2003 was $758,000
as compared to $330,000 for the same period last year, an increase of $428,000.
The cumulative loss from the date of inception, August 24, 1981 to October 31,
2003, amounted to $64,732,000. Such losses are attributable to the fact that we
are still in the development stage and accordingly have not derived sufficient
revenues from operations to offset the development stage expenses.
Liquidity and Capital Resources
We have financed our operations since inception primarily through equity
and debt financing, research product sales and interest income. During the three
months ended October 31, 2003, we had a net increase in cash and cash
equivalents of $1,039,000, which resulted primarily from net cash provided by
financing activities of $2,573,000, which was due to: proceeds from private
placement of common stock and warrants and proceeds from the exercise of
warrants and options offset by net cash used in operating activities of
$1,532,000 and net cash used in investing activities of $2,000. Total cash
resources as of October 31, 2003 were $1,369,000 compared to $330,000 at July
31, 2003.
Our current liabilities as of October 31, 2003 were $2,296,000 compared to
$2,744,000 at July 31, 2003, a decrease of $448,000. The decrease was primarily
due to full payment of unpaid payroll taxes, payment of payables related to our
Phase III clinical trials for malignant mesothelioma and partial payment of
unpaid payroll. As of October 31, 2003 our current liabilities exceeded our
current assets and we had a working capital deficit of $597,000.
Our continued operations will depend on our ability to raise additional
funds through various potential sources such as equity and debt financing,
collaborative agreements, strategic alliances, sale of tax benefits, revenues
from the commercial sale of ONCONASE(R), licensing of our proprietary RNase
technology and our ability to realize the full potential of our technology and
our drug candidates via out-licensing agreements with other companies. Such
additional funds may not become available as we need them or be available on
acceptable terms. Through October 31, 2003, a significant portion of our
financing has been through private placements of common stock and warrants, the
issuance of common stock pursuant to the exercise of stock options and warrants
and for services rendered, debt financing and financing provided by our Chief
Executive Officer. Additionally, we have raised capital through the sale of our
tax benefits. Until and unless our operations generate significant revenues, we
expect to continue to fund operations from the sources of capital previously
described; we are continuing our fund raising efforts and will seek to secure
required financing in the first calendar quarter of 2004. There can be no
assurance that we will be able to raise the capital we need on terms which are
acceptable, if at all. After taking into account the net proceeds we anticipate
to receive from the sale of our tax benefits in December 2003, we believe that
our cash and cash equivalents as of October 31, 2003 will be sufficient to meet
our anticipated cash needs through November 1, 2004. The report of our
independent public accountants on our July 31, 2003 financial statements
included an explanatory paragraph which states that our recurring losses,
working capital deficit and limited liquid resources raise substantial doubt
about our ability to continue as a going concern. Through October 31, 2003, we
continued to incur losses and, as of October 31, 2003, had a working capital
deficiency and limited liquid resources, which raise substantial doubt about the
Company's ability to continue as a going concern. Our financial statements at
October 31, 2003 and July 31, 2003 do not include any adjustments that might
result from the outcome of this uncertainty.
- 11 -
We will continue to incur costs in conjunction with our U.S. and foreign
registrations for marketing approval of ONCONASE(R). We are currently in
discussions with several potential strategic alliance partners, including major
international biopharmaceutical companies, to further the development and
marketing of ONCONASE(R) and other related products in our pipeline. However, we
cannot be sure that any such alliances will materialize.
New Jersey has enacted legislation permitting certain corporations located
in New Jersey to sell state tax loss carryforwards and state research and
development credits or tax benefits. For the state fiscal year 2004 (July 1,
2003 to June 30, 2004), our Company has approximately $1,378,000 of total
available tax benefits of which approximately $261,000 was allocated to be sold
between July 1, 2003 and June 30, 2004. Based on an agreement we entered into,
we will receive approximately $222,000 from the sale of the allocated tax
benefits, which was recognized as a tax benefit for the quarter ended October
31, 2003. In December 2002, we received approximately $229,000 from the sale of
the allocated tax benefits, which was recognized as a tax benefit for the
quarter ended October 31, 2002. We will attempt to sell the remaining balance of
our tax benefits in the amount of approximately $1,117,000 between July 1, 2004
and June 30, 2005, subject to all existing laws of the State of New Jersey.
However, we cannot assure you that we will be able to find a buyer for our tax
benefits or that such funds will be available in a timely manner.
Our common stock was delisted from The Nasdaq SmallCap Market effective at
the close of business April 27, 1999 for failing to meet the minimum bid price
requirements set forth in the NASD Marketplace Rules. As of April 28, 1999, our
common stock trades on the OTC Bulletin Board under the symbol "ACEL.OB".
Delisting of our common stock from Nasdaq could have a material adverse effect
on our ability to raise additional capital, our stockholders' liquidity and the
price of our common stock.
The market price of our common stock is volatile, and the price of the
stock could be dramatically affected one way or another depending on numerous
factors. The market price of our common stock could also be materially affected
by the marketing approval or lack of approval of ONCONASE(R).
Item 3. Quantitative and Qualitative Disclosures About Market Risk
Not applicable.
Item 4. Controls And Procedures.
(a) Evaluation of disclosure controls and procedures.
Under the supervision and with the participation of our management,
including our Chief Executive Officer and acting Chief Financial Officer, we
evaluated the effectiveness of the design and operation of our disclosure
controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act) as
of October 31, 2003, the end of the period covered by this report, the
evaluation date. Based upon the evaluation, the Chief Executive Officer and
acting Chief Financial Officer concluded that, as of the evaluation date, our
disclosure controls and procedures were effective in timely alerting her to the
material information relating to the Company required to be included in our
periodic SEC filings.
(b) Changes in internal controls.
There were no significant changes made in our internal controls during the
period covered by this report or, to our knowledge, in other factors that have
or could significantly affect these controls subsequent to the date of their
evaluation.
- 12 -
PART II. OTHER INFORMATION
Item 2. Changes in Securities and Use of Proceeds
(c) Recent Sales of Unregistered Securities
In August 2003, we issued to private investors an aggregate 120,000 shares
of restricted common stock and five-year warrants to purchase an aggregate
120,000 shares of common stock at an exercise price of $1.25 per share. We
received an aggregate of $60,000 from such private placements. These
transactions were consummated as a private sale pursuant to Section 4(2) of the
Securities Act of 1933, as amended.
From August 2003 to October 2003, we issued an aggregate of 1,229,273
shares of common stock upon the exercise of warrants by unrelated parties, which
resulted in aggregate gross proceeds of $953,455 to us. The issuance of such
shares was consummated as a private sale pursuant to Section 4(2) of the
Securities Act of 1933, as amended, and we have previously registered the resale
of these shares by the stockholders on a Form S-1 registration statement.
In September 2003, we issued to an institutiona1 investor, 1,704,546
shares of restricted common stock and five-year warrants to purchase 852,273
shares of common stock at an exercise of price of $1.50 per share. We received
gross proceeds of $1,500,000 from such private placement. This transaction was
consummated as a private sale pursuant to Section 4(2) of the Securities Act of
1933, as amended, and we have agreed to register on a Form S-1 registration
statement, the resale of these shares by the institutional investor.
In September 2003, we issued 38,710 shares of restricted common stock to
an unrelated party as finder's fee associated with the private placement
amounting to $60,000. This transaction was exempt from registration under
Section 4(2) of the Securities Act of 1933, as amended, and we have agreed to
register the resale of these shares by the stockholder on a Form S-1
registration statement.
The net proceeds from the above mentioned transactions will be used for
general corporate purposes.
Item 6. Exhibits and Reports on Form 8-K
(a) Exhibits (numbered in accordance with Item 601 of Regulation S-K).
Exhibit No. or
Exhibit Incorporation by
No. Item Title Reference
- ------- ---------- ---------
3.1 Certificate of Incorporation ^^^
3.2 Amendment to Certificate of Incorporation, dated
February 1994 ^^^
3.3 Amendment to Certificate of Incorporation, dated
December 26, 1997 ^^^
3.4 By-Laws ^^^
4.1 Certificate of Designation for Series A Preferred
Stock +
4.2 Form of Amended Notes Payable which amends the
November 2001, April 2002, June 2002, July 2002,
September 2002, November 2002 December 2002,
January 2003, March 2003 and May 2003 Notes Payable +
4.3 Form of Subscription Agreement and Warrant
Agreement used in the September and November 2001,
and January, March, April, May, June and October
2002 private placements ^
4.4 Form of Note Payable and Warrant Certificate
entered into November 2001, April, June, July,
September, November and December 2002, and
January, March and May 2003 ^^
- 13 -
Exhibit No. or
Exhibit Incorporation by
No. Item Title Reference
- ------- ---------- ---------
10.1 Securities Purchase Agreement and Warrant Agreement
used in September 2003 private placement +
10.2 Registration Rights Agreement used in September
2003 private placement +
10.3 Form of Subscription Agreement and Warrant
Agreement used in the February 2003 and April
through August 2003 private placements +
31.1 Certification of Chief Executive Officer and Chief
Financial Officer pursuant to Rule 13a-14(a), as
adopted pursuant to Section 302 of Sarbanes-Oxley
Act of 2002 (Section 302 Certification) 31.1
32.1 Certification Chief Executive Officer and Chief
Financial Officer pursuant to 18 U.S.C. Section
1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002 (Section 906
Certification) 32.1
99.1 Factors to Consider in Connection with
Forward-Looking Statements 99.1
^ Previously filed as exhibits to the Company's Registration Statement on
Form S-1 (File No. 333-38136, filed with the SEC on February 21, 2002) and
incorporated herein by reference thereto.
^^ Previously filed as exhibits to the Post-Effective Amendment to Company's
Registration Statement on Form S-1 (File No. 333-38136, filed with the SEC
on March 3, 2002) and incorporated herein by reference thereto.
^^^ Previously filed as exhibits to the Company's Registration Statement on
Form S-1 (filed with the SEC on December 11, 2003) and incorporated herein
by reference thereto.
+ Previously filed as exhibits to the Company's Annual Report on Form 10-K
for the year ended July 31, 2003 and incorporated herein by reference
thereto.
(b) Reports on Form 8-K.
On September 5, 2003, we filed a report on Form 8-K which reported under
Item 5 thereof that we completed a private placement to an institutional
investor resulting in the issuance of 1,704,546 shares of common stock and
warrants to purchase an additional 852,273 shares of common stock at an exercise
price of $1.50 per share. We received gross proceeds of $1,500,000 from such
private placement.
- 14 -
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
ALFACELL CORPORATION
(Registrant)
December 15, 2003 /s/ KUSLIMA SHOGEN
----------------------------------------
Kuslima Shogen, Chief Executive Officer,
Acting Chief Financial Officer
(Principal Executive Officer, Principal
Financial Officer and Chief Accounting
Officer) and Chairman of the Board
- 15 -